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Background: Pharmacists’ roles are expanding to delivering a wider set of professional 7 
services including medication management optimisation, vaccinations and screening 8 
services. Robust research determining whether pharmacists have the capacity to offer such 9 
services in the Australian community pharmacy setting is lacking. This protocol details a 10 
mixed methods study that investigates the variation in pharmacists’ daily tasks and the 11 
workspace they work in as a measure of their workload capacity for expanding pharmacy 12 
services. 13 
 14 
Methods: An observational time and motion study will be conducted in up to twenty 15 
community pharmacies in metropolitan and rural regions of Australia. A trained observer will 16 
follow a pharmacist and record the type, location and duration of tasks undertaken over the 17 
course of their working day. Data will be collected and analysed using the electronic Work 18 
Observation Method By Activity Timing (WOMBAT) tool. Pharmacists’ work patterns will be 19 
described as time for each task, and by proportionating multitasking and interruptions. This 20 
information will be combined with workspace data collected using floor plans, photographs 21 
and a qualitative assessment of the working environment completed by the observer. 22 
Analysis will include heat-mapped floor plans visually highlighting pharmacist movements. 23 
 24 
Discussion: Pharmacists may provide solutions to the strained health workforce and system. 25 
There is limited quantitative evidence on whether pharmacists have the time or work setting 26 
to support such needs. The use of time and motion methodology is novel to Australian 27 
community pharmacy research and the findings will provide a better understanding of 28 
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Community pharmacy is an integral part of the Australian healthcare system through its role 40 
in facilitating access to Pharmaceutical Benefits Scheme (PBS) medicines, ensuring the 41 
quality use of medicines and providing effective healthcare services [1]. Through the Sixth 42 
Community Pharmacy Agreement (6CPA) the Australian Federal government is funding 43 
several programs aimed at improving patient outcomes and expanding the role of community 44 
pharmacy in delivering a wider range of professional primary healthcare services [1]. Existing 45 
programs offered include screening, medication reviews, and the administration of 46 
vaccinations [2, 3]. 47 
 48 
The adoption of community pharmacy-based professional services can result in a number of 49 
potential benefits for service users and health systems. Examples include optimised 50 
management of medications [4], reduced adverse drug events [5], achievement of patient 51 
therapeutic goals, improved clinical outcomes [6, 7], and better management of minor 52 
ailments [8]. Given the increasing time pressures on general practitioners (GP) due to 53 
population growth, an ageing population and rise in chronic diseases, community pharmacists 54 
could potentially provide solutions by taking some functions currently managed by the GP [9, 55 
10]. However, Australia is relatively more cautious about utilising pharmacists to provide 56 
clinical services than other countries [11-13]. For example, non-medical prescribing rights 57 
exclude pharmacists and the co-location of pharmacists into GP practices is still relatively 58 
new within Australia [14, 15]. While there have been projects recommending an increase in 59 
public awareness of pharmacy services, little progress has occurred in the last decade [16]. 60 
Differing economic, policy and workforce issues could be reasons for disparities between 61 
Australia and for example, the UK, US and New Zealand [17, 18]. From a pharmacy 62 
perspective, challenges include lack of remuneration, insufficient staffing levels, absence of 63 
appropriate training, limited private consultation areas, increasing workloads and challenging 64 
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work environments [19-22]. Furthermore, interprofessional collaboration has been hindered 65 
by perceived distrust by some GPs of the commercial interest of pharmacists, potentially 66 
inciting competition and boundary encroachment [23, 24]. However, continual communication 67 
mechanisms, clear defined roles, long-term rapport and external funding have been seen as 68 
major facilitators and more studies are required in this space [23, 24]. Regardless, research 69 
into the capacity of community pharmacists to deliver such services may need to take 70 
precedence. 71 
 72 
Gradual reductions in prescription item profits due to Australian community pharmacy 73 
remuneration agreements have facilitated a change in practice with the profession seeking 74 
alternative income sources and to providing more consumer focused services [22]. However, 75 
the delivery of such services can be affected by, but not limited to, workflow, pharmacy 76 
location, and public and professional relationships [25-27]. Additionally, the pharmacy layout 77 
can enable or impede the activities of staff and consumers [28]. For example, pharmacies in 78 
Australia are required to have an area for consumer consultations that ensures privacy and 79 
confidentiality, although many still take place in the public eye [29]. More recently, 80 
pharmacies that wish to provide certain services such as the administration of flu vaccinations 81 
may only do so in an area screened from the general public space; yet little is known if these 82 
areas are being used as intended [29]. These necessities are to be balanced with consumer 83 
expectations of a retail space that allow ease of movement, finding sought items, and paying 84 
for goods and services [28]. Ultimately, community pharmacies are both a professional 85 
healthcare practice and a retailing business, and architectural challenges are therefore a 86 
balance between comfort, safety, and aesthetics [28, 30]. Further research is required and a 87 
better understanding of pharmacists’ tasks, time spent, their workspace and of the social 88 
interactions that take place within it, may support the advancement of professional pharmacy 89 
services [1, 22, 27]. 90 
 91 
Identifying workflows of healthcare workers can be a challenge, and qualitative approaches 92 
such as interviews and focus groups may rely on the participant’s ability to clearly articulate 93 
needs and tasks [31]. In contrast, reviews by Bratt et al. [32], Lopetegui et al. [33], and Zheng 94 
et al. [34] suggest continuous observation time and motion (TMS) design involving an 95 
external observer following the participant in real-time and continuously recording activity at 96 
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1-second intervals, as being the method of choice for collecting time/duration data in 97 
healthcare. Alternatives such as time efficiency questionnaires (participant’s self-reporting of 98 
own activity) and work-sampling (observations recorded at predetermined intervals) 99 
techniques can potentially lose granularity in data and are generally considered less reliable, 100 
especially when observers need to follow participants travelling across a number of areas, 101 
like in a pharmacy [31, 34, 35]. 102 
 103 
Time and motion methodology has demonstrated its utility in understanding pharmacists’ 104 
workloads in previous studies [19, 31, 36], in Australian hospital pharmacies [37], and in non-105 
Australian community pharmacies [19]. However, little is still known about workflows within 106 
Australian community pharmacies and of the impact of the community pharmacy workspace 107 
on various parameters such as professional practice [38]. 108 
 109 
Comparatively, Australian community pharmacists differ from their hospital colleagues in 110 
terms of their function, remuneration structure, policies, teams they work within, and 111 
resources [18]. Hospital pharmacists are paid more, work in multidisciplinary teams and can 112 
choose to practice providing clinical services, drug information services, and drug policy 113 
administration [18]. Australia shares some commonality with countries such as Canada, 114 
England, and the US in terms of the leading cause of health burden being chronic conditions 115 
such as cardiovascular disease, diabetes mellitus and cancer; and of gradually equipping 116 
community pharmacists with additional patient-centred roles [18, 39]. However, they do have 117 
contrasting geographical challenges, number of practicing pharmacists, health workforce, 118 
multicultural population and the burden of chronic diseases, together with funding, legislative 119 
and policy differences [18, 39-41]. For example, there are notable shortages in access to GP 120 
services in rural, remote and regional Australia [11]. Additionally, the Australian health system 121 
operates on a fee-for-service basis for GPs and many allied health professionals; however, 122 
there is no system level funding structure for community pharmacists [11, 42, 43].  123 
 124 
The diverse nature of Australia’s population, differences in health needs and systems present 125 
unique challenges to the Australian community pharmacy sector. This research will better 126 
inform policymakers and stakeholders as to what community pharmacy services to prioritise. 127 
More importantly, it will add depth to current literature by exploring the use of time and motion 128 
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methodology that is novel to community pharmacy research, and by combining workflow data 129 
with analysis of spatial metrics. 130 
 131 
Lack of well designed, dedicated consultation areas and workspace in pharmacies is often 132 
discussed in relation to the uptake of consultation services, professional identity, error and 133 
workplace satisfaction [27]. Furthermore, employee satisfaction and perceived 134 
productivity/effectiveness, has been shown to be affected by the Indoor Environment Quality 135 
(IEQ) and physical layout (spatial arrangement) of office environments [27, 44, 45]. To better 136 
understand the influence of such workspace parameters on work patterns we wish to 137 
administer a spatial questionnaire that has been developed using industry standard IEQ 138 
dimensions of light, acoustics and design from the Centre for the Built Environment post-139 
occupancy evaluation occupant satisfaction survey [44, 45].  140 
 141 
Such qualitative research has often been combined with behavioural mapping, the systematic 142 
visual documentation of location based human activity [46], to provide information of the 143 
effect of building design [47] on efficiency and wellbeing of pharmacy staff [45, 48], and in 144 
improving the flow of healthcare clinics [49]. In this study, mapping will be informed by data 145 
gathered from pharmacy-user observational research. This will be paired with area metrics 146 
(m2) measured from pharmacy floor plans to inform spatial efficiency scores [50]. 147 
 148 
 149 
Study aims and objectives 150 
 151 
The primary aim of this study is to measure and map community pharmacists’ time and 152 
workspace as a means of informing the feasibility of implementing extended pharmacy 153 
services. 154 
 155 
Our objectives are to quantify the proportion of time spent on different work tasks (such as 156 
dispensing, counselling, sales and waiting), the frequency of each task and of consumer 157 
contact. We will also calculate time spent on multi-tasking and the rate of interruptions and 158 
relate these observations to metrics analysis of existing spatial capacity and pharmacy 159 
layouts. 160 







Study design 167 
 168 
This study has been approved by the University of New South Wales and Curtin University 169 
Human Research Ethics Committees (HREC number HRE2018-0635). 170 
 171 
This research follows a feasibility study that reported pharmacists’ workflow observations over 172 
a period of 35 hours within three Australian community pharmacies [38]. We are now seeking 173 
to extend this to improve the robustness and generalisability of results, investigate whether or 174 
not pharmacy location or type of pharmacy impacts on workflow and also extend the data 175 
collection to include spatial mapping of the pharmacy tenancy area (floor space within the 176 
pharmacy). 177 
 178 
A direct observational time and motion study will be conducted across twenty pharmacies (or 179 
until data saturation occurs) in metropolitan and rural regions of Australia. Initial recruitment 180 
will be sought in Western Australia (WA) and New South Wales (NSW), and thereafter 181 
extended to other states if necessary. The initial restriction to these states is logistical, and we 182 
believe there is enough uniformity of practice between states that results will generalise 183 
across Australia. 184 
 185 
Workspace data will be collected using floor plans, photographs and an environment 186 
questionnaire completed by the observer. This information will be combined with the 187 
observational results to visually highlight areas and patterns of pharmacist movements across 188 
the pharmacy through heat mapping. 189 
 190 
Collected data will be stored primarily in digital format. All data on paper (such as consent 191 
forms) will be stored in locked filing cabinets and all digital data will be stored on password-192 
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protected computers. Data will be retained for at least seven years following results 193 
publication and destroyed in line with current local guidelines. 194 
 195 
 196 
Study participants 197 
 198 
Potential participants will be identified using a snowball strategy where pharmacists known to 199 
the investigator team will be contacted in the first instance, and they then will be asked to 200 
recommend others, who then recommends another. A convenience sample of twenty 201 
pharmacies representative of high and low script volumes (i.e. above and below the average 202 
number across pharmacies in Australia of 140 prescriptions per day per pharmacy) [51] and 203 
metropolitan and rural regions of NSW and WA will be selected (Table 1). 204 
 205 
Table 1: Matrix of initial pharmacy numbers and characteristics. 206 
 207 
Informed written consent will be sought from both the pharmacist to be observed and the 208 
owner(s) allowing us to undertake observational data collection in their pharmacy. 209 
Independent to this, the owners will also be asked to give a separate consent to collect spatial 210 
data including floor plans and location of shop fixtures and lighting. Information will be 211 
provided through verbal and written communication and questions will be welcomed. 212 
 213 
Participation will be voluntary and participants will be able to withdraw from the study at any 214 
time, without explanation or penalty. Should they decide to withdraw, they may give or refuse 215 
permission to use any information collected thus far. 216 
 217 
 218 
Data collection 219 
 220 
During recruitment, no restrictions will be placed on the size of the pharmacy or the number of 221 
pharmacists working at the pharmacy. However, at least one active, practicing pharmacist 222 
(i.e. not just undertaking managerial duties) must agree to be observed per pharmacy for a 223 
total of eighteen hours over a period of three days of the working week, excluding weekends. 224 
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 225 
Pharmacist workflow 226 
 227 
Workflow analysis will be conducted using the Work Observation Method by Activity Timing 228 
(WOMBAT) electronic software installed onto tablet computers [52, 53]. Data will be collected 229 
across four dimensions: (1) What (the task being observed); (2) Where (the location where 230 
the observed task is being undertaken); (3) With (the person/people with the pharmacist at 231 
the time the observed task is being undertaken); and (4) How (how the task is being 232 
completed, for example, using a phone) [38, 54]. A time log of the data will be automatically 233 
recorded by the software. Interruptions, defined as stopping the current task to respond to an 234 
external stimulus and multitasking, defined as performing two tasks simultaneously, will also 235 
be recorded. The same task list and definitions schedule developed and utilised in the pilot 236 
study [38] will be used in this research. It may be amended for clarification during observer 237 
training. 238 
 239 
During observations, posters displayed in highly visible locations around the pharmacy will 240 
notify that pharmacist work patterns are being observed and no data on consumers is being 241 
collected. Consumers will be invited to discuss the study directly with the pharmacist involved. 242 
The observer will not interact with consumers or pharmacists and will cease observing if 243 
requested by the consumer or pharmacist. The observer will not record any conversations or 244 
any information inadvertently witnessed or not related to the study. Confidentiality of the data 245 
will be strictly adhered to and only non-identified information will be used. 246 
 247 
The observer will position in close proximity to the pharmacist without interrupting their flow of 248 
work during observations. Observations will be of two-hour intervals, for six hours per day. A 249 
total of nine sessions will take place over three working weekdays convenient to the 250 
participants. A short break will be scheduled between sessions to help minimise observer 251 
fatigue. Pharmacist-consumer interactions will be noted under general headings such as 252 
‘dispensing of medication’, ‘education’, and ‘sales’. The collecting and reporting checklist 253 
suggested by Zheng et al. [34] for continuous observational time and motion studies will be 254 
used as a guide to ensure data consistency and quality. The observer will not have any 255 
interactions with consumers and no patient and public information will be recorded. 256 
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 257 
Demographic data on pharmacy location, number of employed staff, type of pharmacy 258 
(privately owned versus large chain), and prescription volumes per day (as a measure of 259 
workload) will also be collected. Additionally, the number of pharmacists, pharmacy staff, non-260 
pharmacy staff, prescriptions and sales will be noted for each two-hour session. 261 
 262 
Two observers (one in WA and one in NSW) will familiarise themselves with task definitions 263 
(appendix 1), data collection techniques and the WOMBAT tool. These observers will then 264 
train other employed research assistants if required. Inter-rater reliability testing will be 265 
conducted to assess consistency between observers [55]. During the training, observers will 266 
jointly practice observing and categorising tasks undertaken by a pharmacist participant. 267 
Discrepancies between observers will be discussed and corrected. Consistency will then be 268 
tested with both the trainer and the trainee research assistant independently recording 269 
observations of the same pharmacist, at the same time until there is reasonable uniformity 270 
and good inter-rater reliability scores between all observers. Repeated training sessions and 271 
assessments will be scheduled to clarify observations, rectify discrepancies and achieve 272 
consistency before any further data collection occurs. Task list and definitions will also be 273 
amended during observer trainings if clarification is required. Two research assistant 274 
observers in NSW and two in WA will be employed to collect data. One observer will collect 275 
data at one participating pharmacy at any given time. 276 
 277 
It is acknowledged that the direct, open observational method adopted here may influence 278 
pharmacists’ work patterns where the participant (and other staff or consumers) may feel 279 
anxious, and possibly present an enhancement in performance in the presence of an external 280 
observer [33, 38, 56, 57]. However, these may be reduced with the pharmacist being 281 
observed for extended periods, on multiple occasions and for up to two hours per session, 282 
and by the observer being positioned out of the way of usual practices but close enough to 283 
observe the participant [34, 35]. 284 
  285 
 Pharmacy workspace 286 
 287 
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Pharmacy spaces can be thought of as a complex landscape of holistic health-care provision 288 
and retail where emotion [58] plays a vital role in customer experience [29]. We are seeking 289 
to understand the affects of the work environment and space on pharmacist work patterns. 290 
Data gathered from the WOMBAT software will be combined with area metrics (m2) measured 291 
from the pharmacy floor plans to inform spatial efficiency scores – floor areas of each defined 292 
spatial category (i.e. dispensary, office, consultation and retails areas) expressed as a 293 
percentage of the overall pharmacy area. The observer will request floor plans from owners 294 
that consent to this part of the research. If these are unavailable, the observer will take area 295 
measurements, photographs and sketch floor plans using a commercially available computer-296 
aided design (CAD) and drafting software application (AutoCAD®). The observer will also 297 
complete a qualitative questionnaire (appendix 2) assessing the pharmacy atmosphere [28], 298 
and environment, which includes user responses to environmental stimuli including light, 299 
visual and audible noise, visibility (i.e. height and depth of space) and wayfinding. The 300 
questionnaire will also prompt when supplementary photographs are required to help give 301 
visual context to the entered data. No persons will be included in the photographs. 302 
 303 
Floor plans will be combined with the results from the workflow WOMBAT task dimension (the 304 
amount of time spent in a location) to generate heat maps reflecting patterns of pharmacist’s 305 
movements throughout the day. Collectively, the quantitative and qualitative research will be 306 
used to identify evidence-based design opportunities for effective consultation space and 307 
spatial improvement of pharmacy workspaces. 308 
 309 
 310 
Outcome measures 311 
 312 
The primary outcome will be the frequency of each of particular task and the proportion of 313 
total observation time spent on different tasks. Secondary outcomes will include 314 
documentation of spatial capacity and shop layouts within community pharmacies, mapping 315 
of pharmacist’s movements within the pharmacy area, time spent with consumers and time 316 
spent on professional services. 317 
 318 
 319 
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Analysis 320 
 321 
A total of 360 hours (2 hours x 9 session per pharmacy x 20 pharmacies) of pharmacist 322 
observations are planned: 180 hours in metropolitan areas and 180 hours in rural 323 
pharmacies. 324 
 325 
Pharmacists’ work patterns will be described by calculating task time for each task; proportion 326 
of total observation time on different tasks; proportion of multitasking time; rate of 327 
multitasking; and rate of interruptions. 95% confidence intervals (CIs) for the proportion of 328 
total time and the proportion of time on multitasking will be obtained using the large sample 329 
normal approximations. The interruption rates, including their 95% CIs, will be calculated 330 
using Poisson regression. Other descriptive statistics including number of tasks, average 331 
length of tasks, and frequency of tasks over observation time will also be presented. 332 
 333 
The workspace data, floor plans and photographs will be used to document and categorise 334 
pharmacy space, and generate heat maps. Thematic analysis will be used to identify 335 
emergent spaces, spatial qualities and issues from the questionnaire results using a general 336 
inductive approach [59]. Themes will be grouped and mapped back to each spatial category 337 
(as defined in the WOMBAT tool and floor plan analysis) and then analysed against the 338 
supporting observational data (photographs) to identify causal design parameters that are 339 
impacting (positively or negatively) the overall pharmacy experience for staff and customers; 340 






There is limited quantitative evidence of pharmacists’ work patterns, especially in Australian 347 
community pharmacists. The use of time and motion methodology is novel to community 348 
pharmacy research. This observational workplace study will add depth and breadth to the 349 
understanding of pharmacist’s capacity and the availability of time and workspace to provide 350 
pharmaceutical services. Although the approach may influence the behaviours of 351 
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pharmacist’s being observed appropriate steps will be taken to minimise its effect on the 352 
overall findings. The convenience sampling procedure and the amount of hours of 353 
observation (360 hours over twenty pharmacies) may limit the generalisability of the results. 354 
However, the inclusions of metropolitan and non-metropolitan pharmacies, across two states, 355 
each varying in size, range of resources, type of pharmacy, and workloads will negate such 356 
concerns. 357 
 358 
Healthcare and the health workforce are facing a number of stressors due to population 359 
growth, rise in chronic diseases, and geographical challenges. Better utilisation of 360 
pharmacist’s skills have shown to improve patient outcomes, access to services, and reduced 361 
disease burden, yet their duties are seldom extended to providing clinical services and in 362 
assisting GPs. Even if a number of barriers of Australian health system are negotiated will 363 
pharmacists have the time, workspace, infrastructure or work environment to support such 364 
needs? This study will aid a review of the position of pharmacists amongst other primary care 365 
providers, and direct better ways to broaden capacity to deliver services, meet consumer 366 
demands and possibly improve the application of pharmacists’ skills. The results will add to 367 
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